1. Adler L, Duncan E, Reiter S, Angrist B, Peselow E, Rotrosen J. Effects of calcium-channel antagonists on tardive dyskinesia and psychosis. Psychopharmacol Bull 1988;24:421-425.

2. Adler LA, Peselow E, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. Biol Psychiatry 1992;31:160A.

3. Alpert M, Diamond F, Friedhoff AJ. Receptor sensitivity modification in the treatment of tardive dyskinesia. Psychopharmacol Bull 1982;18:90-92.

4. Alphs LD, Davis JM. Cholinergic treatments for tardive dyskinesia. In: Bannet J, Belmaker RH, eds. New directions in tardive dyskinesia research. Modern problems in pharmacopsychiatry. Vol 21. Basel: Karger, 1983;168-186.

5. Bak TH, Bauer M, Schaub RT, Hellweg R, Reishies FM. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry 1995;56:418-422.

6. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive dyskinesia. Task Force Report 18. Washington, DC: American Psychiatric Association, 1980.

7. Baldessarini RJ, Frankenburg FR. Clozapine—A novel antipsychotic agent. N Engl J Med 1991;324:746-754.

8. Berman I, Zalma A, DuRand C, Green AI. Clozapine induced myoclonic jerks and drop attacks [Letter]. J Clin Psychiatry 1992;53:329-330.

9. Berzewski H, Helmchen H, Hippius H, et al. Das Klinische Wirkungsspektrum eines neuen Dibenzodiazepinederivates. Arzneimittelforschung 1969;19:495-496.

10. Bjorndal N, Casey DE, Gerlach J. Enkephalin, morphine, and naloxone in tardive dyskinesia. Psychopharmacology 1980:69:133-136.

11. Borison RL, McLarnon MC, DeMartines N, Diamond B. Calcium channel antagonists: interaction with dopamine, schizophrenia and tardive dyskinesia. In: Wolf ME, Mosnaim AD, eds. Tardive dyskinesia: biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press, 1988;217-231.

12. Borison RL, Pathiraja AD, Diamond BL, Meibach RD. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218.

13. Browne J, Silver H, Martin R, et al. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia. J Clin Psychopharmacol 1986;6:88-92.

14. Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. New York: Futura, 1992;167-198.

15. Burke RE, Kang UK, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Movement Disord 1989;4:157-175.

16. Buruma OJS, Roos RAC, Bruyn GW, Kemp B, Van Der Velde FA. Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand 1982;65:81-88.

17. Casey DE. Tardive dyskinesia: nondopaminergic treatment approaches. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia—Research and treatment. Psychopharmacology, supplement 2. Berlin: Springer-Verlag, 1985;137-144.

18. Casey DE. Tardive dyskinesia: reversible and irreversible. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia—Research and treatment. Psychopharmacology, supplement 2. Berlin: Springer-Verlag, 1985;88-97.

19. Casey DE. Tardive dyskinesia: In: Meltzer HY, ed. Psychopharmacology: The third generation of progress. New York: Raven Press, 1987;1411-1419.

20. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989;99:S47-S53.

21. Casey DE, Gerlach J, Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology 1974;66:73-77.

22. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? In: Bannet J, Belmaker RH, eds. New directions in tardive dyskinesia research. Basel: Karger, 1983;65-79.

23. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.

24. Chouza C, Caamano JL, Romero S, Lorenzo J, Feres S. Extrapyramidal effects of benzamides. In: Kemali D, Racagni G, eds. Chronic treatments in neuropsychiatry. New York: Raven Press, 1985;43-59.

25. Cole JO, Gardos G, Rapkin RM. Lithium carbonate in tardive dyskinesia and schizophrenia. In: Gardos G, Casey DE, eds. Dyskinesia and affective disorder. Washington, DC: American Psychiatric Press, 1984;49-73.

26. Cole JO, Gardos G, Tarsy D, et al. Drug trials in persistent dyskinesia. In: Fann WE, Smith RC, Davis JM, Domino EF, eds. Tardive dyskinesia: Research and treatment. New York: Spectrum Publications, 1980;419-427.

27. Dave M. Clozapine-related tardive dyskinesia: Case report. Biol Psychiatry 1994;35:886-887.

28. DeLeon J, Leticia M, Camunas C. Clozapine and jaw dyskinesia: a case report. J Clin Psychiatry 1991;52:494-495.

29. Devaux A. Dyskinesies tardives: role de la pyridoxine dans la prevention. Semin Hop Paris 1987;63:1476-1480.

30. Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-777.

31. Elkashef AM, Ruskin PE, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990;147:505-509.

32. Ereshefsky L, LaCombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(Suppl 3):580-588.

33. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33:1255-1261.

34. Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;464-245.

35. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects. J Clin Psychiatry 1994;55(Suppl B):78-81.

36. Freedman R, Bell J, Kirch D. Clonidine therapy for coexisting psychosis and tardive dyskinesia. Am J Psychiatry 1980;137:629-630.

37. Gardos G, Casey D, Cole JO, et al. Ten year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-841.

38. Gardos G, Cole JO. The evaluation and treatment of neuroleptic-induced movement disorders. Harvard Rev Psychiatry 1995;3:130-139.

39. Gelenberg AJ, Dorer DJ, Wojcik JD, Falk WE, Brotman AW, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-153.

40. Gerbino L, Shopsin B, Collora M. Clozapine in the treatment of tardive dyskinesia: an interim report. In: Fann WF, Smith RC, Davis JM, Domino EF, eds. Tardive dyskinesia: Research and treatment. New York: Spectrum Publications, 1980;475-489.

41. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(Suppl B):107-109.

42. Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol plus biperiden, thioridazine, and clozapine. Psychopharmacology 1978;59:105-112.

43. Gouzoulis E, Grunze H, von Bardeleben U. Myoclonic epileptic seizures during clozapine treatment: report of three cases. Eur Arch Psychiatry Clin Neurosci 1991;240:370-372.

44. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:(2):253-273.

45. Haggstrom JE. Sulpiride in tardive dyskinesia. Curr Ther Res 1980;27:164-169.

46. Hay DP, Hay L, Blackwell B, Spiro HR. ECT and tardive dyskinesia. J Geriatric Psychiatr Neurol 1990;3:106-109.

47. Huang CC, Wang RH, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacology 1981;73:359-362.

48. Jankovic J, Arman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind placebo controlled study. Neurology 1987;37:616-623.

49. Janssen PAJ, Niemegeers CJE, Awouters FHL, Schellekens KHL, Megens AAHP, Meert TF. Pharmacology of risperpidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.

50. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988;8:385.485.

51. Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull 1979;5:251-295.

52. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guildford Press, 1982.

53. Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia. Schizophr Res 1992;6:122-123.

54. Kane JM, Honigfeld G, Singer J, Meltzer, MY. Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.

55. Kane JM, Jeste DV, Barnes JRE, et al, eds. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC; American Psychiatric Association, 1992.

56. Kang UJ, Burke RE, Fahn S. Tardive dystonia. Adv Neurol 1988;50:415-429.

57. Kazamatsuri H, Chien C, Cole J. Therapeutic approaches to tardive dyskinesia. Arch Gen Psychiatry 1972;27:491-499.

58. Khot V, Egan MF, Hyde TM, Wyatt RJ. Neuroleptics and classic tardive dyskinesia. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mt. Kisco, NY: Futura, 1992;121-166.

59. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 1994;14:430-431.

60. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993;181:137-138.

61. Lenox RH, Weaver LA, Saran BM. Tardive dyskinesia: clinical and neuroendocrine response to low dose bromocriptine. J Clin Psychopharmacol 1985;5:286-292.

62. Levin H, Chengappa KNR, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992;53:248-251.

63. Lieberman JA. Neuroleptic-induced movement disorders and experience with clozapine in tardive dyskinesia. J Clin Psychiatry 1990;8:3-8.

64. Lieberman JA, Alvir J, Mukherjee S, Kane JM. Treatment of tardive dyskinesia with bromocriptine. Arch Gen Psychiatry 1989;46:908-913.

65. Lieberman J, Johns C, Cooper T, Pollock S, Kane JM. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989;99:S54-S59.

66. Lieberman JA, Saltz BL, Johns CA, Pollack S, Bornstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510.

67. Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976;129:114-119.

68. Lohr JB, Cadet JL, Lohr MA, Jeste DV, Wyatt RJ. Alpha-tocopherol in tardive dyskinesia [Letter]. Lancet 1987;1:913-914.

69. Loonen AJM, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative double-blind, placebo-controlled trial. J Clin Psychopharmacol 1992;12:39-42.

70. Ludatscher JI. Stable remission of tardive dyskinesia by L-Dopa. J Clin Psychopharmacol 1989;9:39-41.

71. Mackay AVP, Sheppard GP. Pharmacotherapeutic trials in tardive dyskinesia. Br J Psychiatry 1979;135:489-499.

72. Miller LG, Jankovic J. Drug-induced movement disorders: an overview. In: Joseph AB, Young RR, eds. Movement disorders in neurology and neuropsychiatry. Boston: Blackwell Scientific, 1992;5-32.

73. Modell JG, Tandon R, Beresford TP. Dopaminergic activity of the antimuscarinic antiparkinsonian agents. J Clin Psychopharmacol 1980;9:347-351.

74. Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993;13:204-209.

75. Mouret J, Khomais M, Lemoine P. Low doses of insulin as a treatment of tardive dyskinesia: a double-blind, placebo-controlled study. 17th CINP Meeting, Kyoto, Japan 1990;1:155A.

76. Nasrallah HA, Dunner FJ, McCalley-Whitters M, et al. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. J Clin Psychiatry 1986;47:56-59.

77. Nishikawa T, Tanaka M, Tsuda A, Kuwahara H, Koga I, Uchida Y. Effect of ceruletide on tardive dyskinesia: a pilot study of quantitative computer analyses on electromyogram and microvibration. Psychopharmacology 1986;90:5-8.

78. Pakkenberg H, Pedersen B. Medical treatment of dystonia. In: Casey DE, Chase TN, Christensen AV, Gerlach J, eds. Dyskinesia—Research and treatment. Psychopharmacology, supplement 2. Berlin: Springer-Verlag, 1985;111-117.

79. Peuskens J. Risperidone in the treatment of patients with schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726.

80. Richardson MA. Amino acids in psychiatric disease. American Psychiatric Press, 1990.

81. Richardson MA, Bevans M, Weber J, Gonzales J, Flynn C, Amira L. A dietary intervention decreases TD symptoms. 149th APA Annual Meeting. New York, NY;1994.

82. Sandyk R, Fisher H. Serotonin in involuntary movement disorders. Int J Neurosci 1988;42:185-205.

83. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.

84. Schrodt GR, Wright JH, Simpson R, Moore DP, Chase S. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry 1982;43:328-331.

85. Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992;149:391-393.

86. Shriqui CL, Nobecourt D, Rousseau E, Arnott W. Clinical efficacy of risperidone in a patient with severe tardive dyskinesia. Neuropsychopharmacology 1994;10(Suppl 2):242A.

87. Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology, 1978;56:75-80.

88. Simpson GM, Yadalam KG, Stephanos MJ. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia. J Clin Psychopharmacol 1988;8:49s-51s.

89. Soni SD, Freeman HL, Hussein EM. Oxypertine in tardive dyskinesia: an 8-week controlled study. Br J Psychiatry 1984;144:48-52.

90. Szymanski S, Maune R, Gordon MF, Lieberman J. A selective review of recent advances in the management of tardive dyskinesia. Psychiatr Ann 1993;23:209-215.

91. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55:(Suppl B):102-106.

92. Tandon R, Kane JM. Neuropharmacologic basis for clozapine's unique profile. Arch Gen Psychiatry 1993;50:158-159.

93. Thaker GK, Ferraro TN, Hare TA, Tamminga CA. Pathophysiology and therapy of tardive dyskinesia: the GABA connection. In: Wolf ME, Mosnaim AD, eds. Tardive dyskinesia—Biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press, 1988;199-215.

94. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus [Letter]. Lancet 1987;1:322.

95. van Putten T, Wirshing W, Marder S. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol 1990;10:387-382.

96. Wirshing W, Ames D, Cummings JL, et al. Selegiline and akathisia, tardive dyskinesia and negative symptoms. 18th CINP Meeting, Nice, France 1992;3:17-65.

97. Wolf ME, Koller WC. Tardive dystonia: treatment with trihexyphenidyl. J Clin Psychopharmacol 1985;5:247-248.

98. Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 1986;143:912-914.

99. Yassa R, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986;73:629-633.